2.08
Schlusskurs vom Vortag:
$1.73
Offen:
$1.79
24-Stunden-Volumen:
130.94K
Relative Volume:
3.27
Marktkapitalisierung:
$11.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.5213
EPS:
-3.99
Netto-Cashflow:
$-12.27M
1W Leistung:
+27.61%
1M Leistung:
+27.22%
6M Leistung:
-48.13%
1J Leistung:
-47.74%
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Vergleichen Sie APRE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
APRE
Aprea Therapeutics Inc
|
2.08 | 9.02M | 0 | -14.29M | -12.27M | -3.99 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-12-16 | Eingeleitet | Berenberg | Buy |
2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
2019-10-28 | Eingeleitet | JP Morgan | Neutral |
2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
What analysts say about Aprea Therapeutics Inc. stockOverwhelming profit margins - jammulinksnews.com
Aprea Therapeutics Inc. Stock Analysis and ForecastTriple-digit wealth increases - Autocar Professional
Is Aprea Therapeutics Inc. a good long term investmentLightning-fast growth - jammulinksnews.com
What drives Aprea Therapeutics Inc. stock priceUnmatched profit potential - Autocar Professional
Franklin Covey Co. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com
What analysts say about AMBO stockExplosive earning power - Jammu Links News
Why Aprea Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Courses - Newser
What makes Aprea Therapeutics Inc. stock price move sharplyFree Access to Investment Community - Newser
How Rocky Mountain Chocolate Factory Inc. stock performs during market volatilityFree Consultation - Newser
How Aprea Therapeutics Inc. stock performs during market volatilityConsistent High Return Strategy - Newser
Aprea Therapeutics Insiders Still US$86k Away From Original Investment Value - simplywall.st
Aprea Therapeutics (NASDAQ:APRE) Trading 4.4% Higher – What’s Next? - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MSN
Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers - MSN
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics (APRE) Reports Promising Data on APR-1051 for HPV+ Cancer | APRE Stock News - GuruFocus
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center - Morningstar
Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
CoreWeave Stock Skyrockets 137% In A Month: Hold Or Fold? - Barchart.com
Block Inc. Has Unusual Put Option ActivityShowing Bullish XYZ Investors - Barchart.com
Ostara Inc. Launches CG P2X In Western Canada: Phosphorus, Perfected - Barchart.com
Stocks In Play: WSP Global Inc. - Barchart.com
Alzheimer’s Disease Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Dry Eye Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - Barchart.com
Supporting 2SLGBTQI+ Communities For A Safer, More Equitable And Inclusive Canada - Barchart.com
Artios' AACR Data Success: What It Means For Aprea Therapeutics' ATRN-119 Program - Barchart.com
REKO INTERNATIONAL GROUP INC. TO BUY BACK UP TO 276,066 OF ITS COMMON SHARES - Barchart.com
Aprea Therapeutics Confirms Directors and Accounting Firm - TipRanks
Stocks Finish Sharply Higher On A Resilient US Labor Market - Barchart.com
Compass Refresh, Inc. Launches New Headquarters in Sulphur Springs, TX – Bringing High-Quality Exterior Maintenance Across the Southern Region - Barchart.com
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Stocks In Play: Aimia Inc. - Barchart.com
ADF GROUP INC. Q1-2026 CONFERENCE CALL INVITATION - Barchart.com
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):